Revenue Update on Bellerophon Therapeutics Inc(NASDAQ:BLPH)

Bellerophon Therapeutics Inc(NASDAQ:BLPH) announced the earnings results for Fiscal Year 2016 and Q2. The results came in during Pre-market on Aug 9, 2016. Earnings per share were $-0.39. Analysts had estimated an EPS of $-0.51.

Bellerophon Therapeutics Inc (BLPH) made into the market gainers list on Wednesdays trading session with the shares advancing 1.27% or 0.02 points. Due to strong positive momentum, the stock ended at $1.59, which is also near the day’s high of $1.61. The stock began the session at $1.53 and the volume stood at 29,289 shares. The 52-week high of the shares is $7.64 and the 52 week low is $1.09. The company has a current market capitalization of $23 M and it has 1,45,99,294 shares in outstanding.

Several Insider Transactions has been reported to the SEC. On May 18, 2016, Jonathan M Peacock (CEO) purchased 5,000 shares at $1.37 per share price.Also, On May 22, 2015, Martin Meglasson (Chief Scientific Officer) purchased 712 shares at $8.40 per share price.On Feb 24, 2015, North America, Inc. Linde (10% owner) purchased 358,916 shares at $12.00 per share price, according to the Form-4 filing with the securities and exchange commission.

Bellerophon Therapeutics Inc. is a clinical-stage therapeutics company. The Company is focused on developing products at the intersection of drugs and devices that address medical needs in the treatment of cardiopulmonary and cardiac diseases. The Company has two programs in development. The first program INOpulse is based on its pulsatile nitric oxide delivery device. The Company is developing two product candidates under its INOpulse program: one for the treatment of pulmonary arterial hypertension (PAH) and the other for the treatment of pulmonary hypertension associated with chronic obstructive pulmonary disease (PH-COPD) which is in Phase II development. Its second program is bio absorbable cardiac matrix (BCM) which is in a placebo-controlled clinical trial. The Company is developing BCM for the prevention of cardiac remodeling which leads to congestive heart failure following an ST-segment elevated myocardial infarction (STEMI).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *